<DOC>
	<DOCNO>NCT01501214</DOCNO>
	<brief_summary>The hypothesis randomize double blind study live birth rate significantly high use atosiban prior embryo transfer patient undergo vitro fertilization ( IVF ) treatment . This study aim compare live birth rate IVF treatment patient receive atosiban placebo prior transfer .</brief_summary>
	<brief_title>Use Atosiban Vitro Fertilization ( IVF ) Treatment</brief_title>
	<detailed_description>In-vitro fertilization-embryo transfer ( IVF-ET ) treatment involve multiple follicular development follow ovarian stimulation , oocyte retrieval ET fertilization . Despite recent advance ovarian stimulation , method assist fertilization improved culture condition , implantation potential embryo remain around 20-25 % long time . ET final step IVF cycle success depend embryo quality , endometrial receptivity uterine contraction . Uterine contraction play important role embryo implantation ( Fanchin , 2009 ) excessive uterine contraction may expel embryos uterus decrease implantation potential embryo ( Fanchin et al. , 1998 ) . Ovarian stimulation use great majority IVF program multiple embryos available selection transfer . However , supraphysiological concentration oestradiol follow ovarian stimulation may induce endometrial production oxytocin , formation oxytocin receptor , indirectly formation/release PGF2a ( Richter et al. , 2004 ; Liedman et al. , 2008 ) . It show uterine contractile activity IVF cycle increase approximately 6-fold measure ET compare situation ovulation natural cycle ( Ayoubi et al. , 2003 ) . Fanchin et al . ( 1998 ) estimate 30 % patient undergoing ET pronounce uterine contraction . Uterine contraction also trigger excessive cervical manipulation difficult transfer procedure ( Fanchin et al. , 1998 ) . Drugs inhibit increase uterine contraction time ET attractive approach improve IVF success . However , use beta agonist non-steroid anti-inflammatory drug show provide sufficient benefit ( Bernabeu et al. , 2006 ; Moon et al. , 2004 ; Tsirigotis et al. , 2000 ) . Uterine contraction involve oxytocin therefore inhibition oxytocin receptor may improve IVF success decrease uterine contraction , interfere PGF2a/oxytocin system possibly improve endometrial perfusion ( Vedernikov et al. , 2006 ) . Atosiban , combine oxytocin/vasopressin V1A antagonist , currently register clinical use woman suffer preterm labour . In multicentre , randomize , placebo-controlled trial , show reduce frequency amplitude uterine contraction egg donor compare placebo ( Blockeel et al. , 2009 ; Pierson et al. , 2009 ; Visnova et al. , 2009 ) . There lack embryotoxic effect atosiban concentration 50-fold therapeutic blood concentration ( Pierzynski et al. , 2007 ) . Atosiban affect survival 1-cell rabbit embryo , decrease percentage hatch rabbit blastocyst . The human sperm motility bioassay also show adverse influence .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Atosiban</mesh_term>
	<mesh_term>Vasotocin</mesh_term>
	<criteria>Age &lt; 43 year Normal uterine cavity show ultrasound scan Age &gt; =43 Three previous IVF cycle Use donor oocytes Natural IVF IVM cycle Abnormal uterine cavity ultrasound scan ET cancel absent fertilization risk ovarian hyperstimulation syndrome Blastocyst transfer Undergoing preimplantation genetic diagnosis Recruited study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>atosiban</keyword>
	<keyword>vitro fertilization</keyword>
	<keyword>subfertility</keyword>
</DOC>